Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO
Filter by Topic
ASCO 2014 Highlights
ASCO 2014 – Colorectal and Head & Neck Cancer
ASCO 2014 – Immuno-Oncology
ASCO 2014 – Lung Cancer
ASCO 2015 - Lung Cancer
ASCO 2015 Highlights
ASCO 2016 – Lung Cancer
ASCO 2017 – Multiple Myeloma
ASCO 2018 Insights
ASCO 2019
ASCO 2020 Cholangiocarcinoma
ASCO Breast Cancer Symposium
ASCO Quality Care Symposium
ASCO’s 1st Quality Care Symposium
Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate-017/057 2-y update and exploratory cytokine profile analyses
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer and good performance status
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC)
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–positive NSCLC
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Genetic Abnormality Pinpointed for Intensive Therapy in Wilms Tumor
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—In children who are at risk for Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy. The abnormality—loss of heterozygosity (LOH) on chromosomes 1p and 16q (LOH 1p/16q)—is associated with worse prognosis in children with Wilms tumor.
Read Article
Two Large National Personalized Medicine Clinical Trials Are Launched by ASCO and NCI
By
Dana Taylor
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—Precision medicine in oncology is now being studied in clinical trials in oncology. These trials will pair a patient’s tumor molecular profile with drugs that address those tumor variants.
Read Article
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
By
Wayne Kuznar
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—Lenvatinib (Lenvima) added to everolimus (Afinitor) extended overall survival (OS) significantly compared with everolimus alone in patients with metastatic renal-cell carcinoma (RCC). This phase 2 study also demonstrated improved progression-free survival (PFS) with lenvatinib alone and in combination with everolimus compared with everolimus alone.
Read Article
Page 5 of 19
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma